Kenya vs Thailand: Average cost of multi drug-resistant tuberculosis treatment
Kenya
1,800 constant 2022 US$
in 2024
Thailand
1,823 constant 2022 US$
in 2024
Kenya rank
26th
Thailand rank
25th
Average cost of multi drug-resistant tuberculosis treatment over time
- Kenya
- Thailand
How they compare
Thailand currently reports 1,823 constant 2022 US$ against 1,800 constant 2022 US$ in Kenya, a difference of 23 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Thailand ahead.
Kenya ranks 26th and Thailand ranks 25th of 92 countries.
Thailand has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kenya | Thailand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,883 constant 2022 US$ | 3,461 constant 2022 US$ | 578 constant 2022 US$ | Thailand |
| 2020s | 1,706 constant 2022 US$ | 2,196 constant 2022 US$ | 489.4 constant 2022 US$ | Thailand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Kenya or Thailand?
- Thailand, at 1,823 constant 2022 US$ against 1,800 constant 2022 US$ in Kenya as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Kenya and Thailand?
- 23 constant 2022 US$, with Thailand ahead.
- How many years of comparable data are there for Kenya and Thailand?
- 8 years are reported by both, from 2017 to 2024.
- How do Kenya and Thailand rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Kenya ranks 26th and Thailand ranks 25th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.